araag2/TREC_Precision-Medicine huggingface dataset:
Patient case: 64-year-old male with bladder cancer; genetic feature: FGFR3 (S249C)

Clinical trial: Loop Resectoscope in Treating Patients With Bladder Cancer or Benign Prostatic Hyperplasia Who Are Undergoing Transurethral Resection

Summary: RATIONALE: Transurethral resection is a less invasive type of surgery for bladder cancer or benign prostatic hyperplasia. Transurethral resection using a loop resectoscope may have fewer side effects and improve recovery.
  PURPOSE: This clinical trial is studying how well the loop resectoscope works in treating patients with bladder cancer or benign prostatic hyperplasia who are undergoing transurethral resection.

Detailed description: OBJECTIVES:
  -  Determine the efficacy, in terms of mechanical capabilities, of the Roei loop resectoscope in patients with bladder cancer or benign prostatic hyperplasia undergoing transurethral resection of bladder tumor or benign prostatic adenoma.
  -  Determine the quality of specimens submitted for histological analysis from patients undergoing this procedure.
  OUTLINE: This is an open-label, pilot study.
  Patients undergo transurethral resection using the Roei loop resectoscope. Surgeon satisfaction with the Roei loop resectoscope is measured by a self-assessment questionnaire. The quality of specimens submitted for histological study are also assessed.
  PROJECTED ACCRUAL: A total of 24 patients will be accrued for this study.

Eligibility: DISEASE CHARACTERISTICS:
  -  Diagnosis of bladder cancer or benign prostatic hyperplasia
  PATIENT CHARACTERISTICS:
  -  Not specified
  PRIOR CONCURRENT THERAPY:
  -  Not specified

Relevance to patient case: not relevant
Patient case: 64-year-old male with bladder cancer; genetic feature: FGFR3 (S249C)

Clinical trial: Evaluate the Effect of Growth Hormone (GH) Treatment on Fibroblast Growth Factor 23, a Known Phosphaturic Agent

Summary: The purpose of this study is to evaluate the effect of growth hormone treatment on phosphorus levels in the body. Phosphorus is an important mineral for bone growth. It is well known that growth hormone treatment improves bone density and bone mineral content. The amount of phosphorus is maintained by the kidneys. Fibroblast Growth Factor 23 has recently been recognized to help kidneys control phosphate levels.

Detailed description: This study will compare Fibroblast Growth Factor 23 levels in children with and without growth hormone deficiency. Children with growth hormone deficiency will have levels taken before starting growth hormone replacement and after it has been initiated.

Eligibility: Inclusion Criteria:
  -  Twenty children with significant short stature < 3rd percentile, ages 3-14 years, and referred to Children's Hospital of Alabama
  -  Normal healthy volunteer children 3-18 years with normal stature
  Exclusion Criteria:
  -  Patients on medication including GH
  -  Patients with concomitant hormonal abnormalities
  -  Patients with disorders of calcium and phosphate metabolism
  -  Active neoplasms
  -  Closed epiphysis
  -  Known bone disorders

Relevance to patient case: not relevant
Patient case: 64-year-old male with bladder cancer; genetic feature: FGFR3 (S249C)

Clinical trial: Blood Collection From Individuals With Lung Disease for Genetic Studies

Summary: This is a research study where researchers are collecting blood to evaluate the genetic characteristics of individuals with chronic lung diseases, including asthma, chronic obstructive pulmonary disease (COPD), interstitial lung disease, cystic fibrosis, and lung cancer.

Detailed description: The investigators hope to be able to identify an association between a genetic make-up in the blood samples and the risks of developing a particular lung disease, or severity of a lung disease. The findings of this study might be important to develop future preventative methods and potential treatments for the management of lung disease. The investigators aim to collect blood samples from 300 people with lung disease and 300 controls over 5 years.

Eligibility: Inclusion Criteria:
  -  Must provide informed consent
  -  Males and females, age 18 years and older
  -  Lung disease proven by at least one of the following:
  -  symptoms consistent with pulmonary disease
  -  chest X-rays consistent with lung disease
  -  pulmonary function tests consistent with lung disease
  -  lung biopsy consistent with lung disease
  -  family history of lung disease
  -  disease of organs with know associated with lung disease
  -  individuals suspected of history of lung disease based on history and/or physical examination
  -  normal controls (individuals without history of lung disease) to be sampled to provide a comparison to the lung disease cohort.
  Exclusion Criteria:
  -  Drug and/or alcohol abuse within the past six months
  -  Females who are pregnant or nursing

Relevance to patient case: not relevant
Patient case: 64-year-old male with bladder cancer; genetic feature: FGFR3 (S249C)

Clinical trial: Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases

Summary: This study will evaluate the safety, tolerability and efficacy of SU011248 in patients with non-small cell lung cancer with brain metastases.


Eligibility: Inclusion Criteria:
  -  Patients with radiologically proven brain metastases secondary to non-small cell lung cancer
  -  Received previous whole brain radiation therapy and none, 1 or 2 prior systemic therapy for the treatment of advanced/metastatic non-small cell lung cancer
  Exclusion Criteria:
  -  Patients with brainstem lesions, spinal cord compression. carcinomatous meningitis, or leptomeningeal disease.
  -  Brain metastases >4 cm in any linear direction
  -  Intracranial or intratumoral hemorrhage

Relevance to patient case: not relevant
Patient case: 64-year-old male with bladder cancer; genetic feature: FGFR3 (S249C)

Clinical trial: Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

Summary: This study will assess the safety and efficacy of botulinum toxin Type A for the treatment of urinary incontinence overactive bladder in patients with a spinal cord injury or multiple sclerosis.

Detailed description: Botulinum toxin Type A 300U has been discontinued from the study after regulatory approval of botulinum toxin Type A 200U. Patients remaining in the study who were allocated to receive botulinum toxin Type A 300U at treatment 2 (and had not yet received it) will receive botulinum toxin Type A 200U instead.

Eligibility: Inclusion Criteria:
  -  Urinary incontinence as a result of neurogenic overactive bladder due to spinal cord injury or multiple sclerosis
  -  Inadequate response to anticholinergic medication used to treat overactive bladder.
  -  Neurological respiratory impairment and abnormal pulmonary function test results
  Exclusion Criteria:
  -  History or evidence of pelvic or urologic abnormality
  -  Previous or current diagnosis of bladder or prostate cancer
  -  Symptomatic or untreated urinary tract infection at time of enrollment

Relevance to patient case: not relevant
Patient case: 64-year-old male with bladder cancer; genetic feature: FGFR3 (S249C)

Clinical trial: Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

Summary: The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A in treating overactive bladder in spinal cord injury or multiple sclerosis patients


Eligibility: Inclusion Criteria:
  -  Urinary incontinence as a result of neurogenic overactive bladder due to spinal cord injury or multiple sclerosis
  -  Inadequate response to anticholinergic medication used to treat overactive bladder
  Exclusion Criteria:
  -  History or evidence of pelvic or urologic abnormality
  -  Previous or current diagnosis of bladder or prostate cancer
  -  Urinary tract infection at time of enrollment

Relevance to patient case: not relevant
Patient case: 64-year-old male with bladder cancer; genetic feature: FGFR3 (S249C)

Clinical trial: Cetuximab in Treating Patients With Ménétrier Disease at High Risk of Developing Stomach Cancer

Summary: RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
  PURPOSE: This clinical trial is studying how well cetuximab works in treating patients with Ménétrier disease at high risk of developing stomach cancer.

Detailed description: OBJECTIVES:
  -  Evaluate clinical and biochemical parameter response in patients with Ménétrier disease at high risk of developing gastric cancer treated with cetuximab.
  OUTLINE: This is a non-randomized study.
  Patients receive cetuximab IV on days 1, 8, 15, and 22. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
  Patients complete a quality of life questionnaire at baseline and during week 4.
  PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study.

Eligibility: DISEASE CHARACTERISTICS:
  -  Histologically confirmed Ménétrier disease
  -  Symptomatic disease, including gastrointestinal symptoms which interfere with daily life
  -  Patient is considering surgery
  -  Must have failed medical therapy that was given for 6 months
  -  No Helicobacter pylori infection
  PATIENT CHARACTERISTICS:
  -  Not pregnant or nursing
  -  Negative pregnancy test
  -  Fertile patients must use effective contraception
  -  No NYHA class III-IV cardiovascular disease
  -  No clinically unstable pulmonary disease
  -  No chronic disease requiring ongoing therapy for stabilization, including any of the following:
  -  Uncontrolled diabetes mellitus
  -  Malignancy
  -  Thyroid disease
  -  Hypertension
  -  Active infections requiring systemic antibiotics, antivirals, or antifungals
  -  Uncontrolled seizure disorder
  -  Active neurological disease
  -  No unstable coagulation disorders (e.g., hemorrhagic diatheses or active bleeding disorders) that require medical management
  PRIOR CONCURRENT THERAPY:
  -  Not specified

Relevance to patient case: not relevant
Patient case: 64-year-old male with bladder cancer; genetic feature: FGFR3 (S249C)

Clinical trial: Different Factors Affecting Patients With Newly Diagnosed Bladder Cancer

Summary: RATIONALE: Studying different factors that effect patients with newly diagnosed bladder cancer may help doctors learn more about the disease, improve the ability to plan cancer treatment, and help patients live more comfortably.
  PURPOSE: This clinical trial is studying different factors affecting patients with newly diagnosed bladder cancer.

Detailed description: OBJECTIVES:
  -  To assess the effect of lifestyle factors (e.g., smoking, dietary habits, fluid intake, or environmental exposures) on the recurrence and progression of bladder cancer.
  -  To assess the impact of selenium and/or vitamin E on the progression and recurrence of bladder cancer.
  -  To study health-related quality of life and its association with recurrence and progression of bladder cancer.
  -  To establish a bladder cancer tissue bank that will comprise blood, urine, and bladder tissue.
  -  To study the predictive effect of molecular markers on the recurrence and progression of bladder cancer.
  OUTLINE: This is a multicenter study.
  The study will be based on a cohort of patients with newly detected bladder cancer in all 16 urological centres within the West Midlands, commencing in late 2005 for a period of 5 years. This research project consists of 5 individual studies: CRUK-BCPP-2005-01-COHORT, CRUK-BCPP-2005-01-MARKERS, CRUK-BCPP-2005-01-QOL, CRUK-BCPP-2005-01-TISSUE-BANK, and CRUK-BCPP-2005-01-TREATMENT. Patients may participate in all or only some of these individual studies.
  Peer Reviewed and Funded or Endorsed by Cancer Research UK.

Eligibility: DISEASE CHARACTERISTICS:
  -  Bladder lesion with cystoscopic characteristics compatible with urothelial cancer or transitional cell carcinoma meeting 1 of the following criteria:
  -  Non-muscle-invasive tumor
  -  Muscle-invasive tumor
  -  Solitary G1 pTa tumor
  -  No previous diagnosis of cancer of the urethra, bladder, ureter, or renal pelvis within the 10 years prior to current diagnosis
  PATIENT CHARACTERISTICS:
  -  Fit for cystoscopy and surgical biopsy/resection
  -  No HIV infection
  -  No condition that, in the opinion of the local investigator, might interfere with the safety of the patient or evaluation of the study objectives
  PRIOR CONCURRENT THERAPY:
  -  Not specified

Relevance to patient case: not relevant
Patient case: 64-year-old male with bladder cancer; genetic feature: FGFR3 (S249C)

Clinical trial: Quality of Life in Patients With Bladder Cancer

Summary: RATIONALE: Studying quality of life in patients with bladder cancer may help determine the long-term effects of bladder cancer and may help improve the quality of life for patients in the future.
  PURPOSE: This clinical trial is studying quality of life in patients with bladder cancer.

Detailed description: OBJECTIVES:
  -  To study the effects of recurrence and progression on health-related quality of life (HRQL).
  -  To study the effects of repeat cystoscopy on HRQL.
  -  To study the patients' assessments of a hypothetical prognostic model and how this affects their preference for the mode of surveillance.
  OUTLINE: This is a multicenter study.
  Quality-of-life questionnaires developed by the European Organization for Research and Treatment for Cancer (EORTC) will be used. The EORTC QLQ-BLS24 with 24 questions specific to non-muscle-invasive bladder cancer and the EORTC QLQ-BLM30 with 30 questions specific to muscle-invasive bladder cancer will be combined and used in conjunction with the general cancer questionnaire QLQ-C30.
  Assessments using the QLQ-C30 will be made at baseline in the entire cohort of patients. Follow-up assessments using the QLQ-C30, QLQ-BLS24, and QLQ-BLM30 167 will be made at first routine follow-up and annually until the end of study.
  Peer Reviewed and Funded or Endorsed by Cancer Research UK.

Eligibility: DISEASE CHARACTERISTICS:
  Inclusion criteria:
  -  Enrolled on parent protocol CRUK-BCPP-2005-01
  -  Bladder lesion with cystoscopic characteristics compatible with urothelial cancer or transitional cell carcinoma meeting 1 of the following criteria:
  -  Non-muscle-invasive tumor
  -  Muscle-invasive tumor
  -  Solitary G1 pTa tumor
  Exclusion criteria:
  -  Previous diagnosis of cancer of the urethra, bladder, ureter, or renal pelvis within the 10 years prior to current diagnosis
  PATIENT CHARACTERISTICS:
  Inclusion criteria:
  -  Fit for cystoscopy and surgical biopsy/resection
  Exclusion criteria:
  -  HIV infection
  -  Any condition that, in the opinion of the local investigator, might interfere with the safety of the patient or evaluation of the study objectives
  PRIOR CONCURRENT THERAPY:
  -  Not specified

Relevance to patient case: not relevant
Patient case: 64-year-old male with bladder cancer; genetic feature: FGFR3 (S249C)

Clinical trial: Effect of Dietary, Lifestyle, and Environmental Factors on Patients With Early-Stage Bladder Cancer

Summary: RATIONALE: Learning about the long-term effects of dietary, lifestyle, and environmental factors on the risk of cancer progression and recurrence may help the study of bladder cancer in the future.
  PURPOSE: This clinical trial is studying how dietary, lifestyle, and environmental factors affect patients with early-stage bladder cancer.

Detailed description: OBJECTIVES:
  -  To examine if common and potentially modifiable dietary, lifestyle, and environmental exposures affect the risk of recurrence and progression in bladder cancer.
  OUTLINE: This is a multicenter study.
  Detailed information will be collected about the patients' lifestyle and their exposure to risk factors associated with bladder cancer using semi-structured questionnaires. A baseline questionnaire will be administered at the time of diagnosis and will collect information about socio-demographics, environmental exposures, medical history, diet, health-related quality of life, and social support.
  Further questionnaires will be administered at regular follow-up visits to capture information relating to changes in exposure. A postal questionnaire will be used to collect historical information that may require the patient to check records or consult family or friends. Patients will also be asked to keep a 1-week food, fluid, and micturition diary.
  Patients continue to complete questionnaires at 3 months and then annually for up to 5 years.
  Peer Reviewed and Funded or Endorsed by Cancer Research UK.

Eligibility: DISEASE CHARACTERISTICS:
  Inclusion criteria:
  -  Enrolled on parent protocol CRUK-BCPP-2005-01
  -  Bladder lesion with cystoscopic characteristics compatible with urothelial cancer or transitional cell carcinoma
  -  Histologically proven urothelial cancer meeting one of the following criteria:
  -  Stage Ta (WHO grade 2/3, or grade 1 tumors that are either multifocal or > 3 cm in size)
  -  Stage T1 (any grade)
  -  Stage Tis
  Exclusion criteria:
  -  Previous diagnosis of cancer of the urethra, bladder, ureter, or renal pelvis within the 10 years prior to current diagnosis
  PATIENT CHARACTERISTICS:
  Inclusion criteria:
  -  Fit for cystoscopy and surgical biopsy/resection
  Exclusion criteria:
  -  HIV infection
  -  Any condition that, in the opinion of the local investigator, might interfere with the safety of the patient or evaluation of the study objectives
  PRIOR CONCURRENT THERAPY:
  -  Not specified

Relevance to patient case: not relevant
Patient case: 64-year-old male with bladder cancer; genetic feature: FGFR3 (S249C)

Clinical trial: Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

Summary: The purpose of this study is to explore the effectiveness and safety of several doses of botulinum toxin type A in treating overactive bladder in patients with spinal cord injury.


Eligibility: Inclusion Criteria:
  -  Urinary incontinence as a result of neurogenic overactive bladder due to spinal cord injury
  -  Inadequate response to anticholinergic medication used to treat overactive bladder
  Exclusion Criteria:
  -  History or evidence of pelvic or urologic abnormality
  -  Previous or current diagnosis of bladder or prostate cancer
  -  Urinary tract infection at time of enrollment

Relevance to patient case: not relevant
Patient case: 64-year-old male with bladder cancer; genetic feature: FGFR3 (S249C)

Clinical trial: Multi Center Study to Obtain Bladder Tissue Specimens From Patients Undergoing Transurethral Resection Biopsy Procedure

Summary: The objective of the study is to obtain bladder tissue specimens from patients otherwise undergoing cystoscopy for use in research at Tengion, Inc.


Eligibility: Inclusion Criteria:
  -  Subjects 18-90 years and undergoing TURBT
  -  Willing and able to give signed informed consent
  Exclusion Criteria:
  -  Known active infection
  -  Known colonization with MRSA or VRE
  -  Receipt of blood or blood products for transfusion during the previous 3 months

Relevance to patient case: not relevant
Patient case: 64-year-old male with bladder cancer; genetic feature: FGFR3 (S249C)

Clinical trial: Selenium in Preventing Cancer Recurrence in Patients With Bladder Cancer

Summary: RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of selenium may keep bladder cancer from growing or coming back. It is not yet known whether selenium is more effective than a placebo in preventing cancer recurrence in patients with bladder cancer.
  PURPOSE: This randomized phase III trial is studying selenium to see how well it works compared with a placebo in preventing cancer recurrence in patients with bladder cancer.

Detailed description: OBJECTIVES:
  Primary
  -  To determine the effect of selenium, when administered with standard care, in preventing the recurrence of bladder cancer in patients with non-muscle-invasive transitional cell carcinoma of the bladder at risk for recurrence.
  Secondary
  -  To determine the effect of selenium on the recurrence of bladder cancer, in terms of histological type, number, and size.
  OUTLINE: Patients are randomized to 1 of 2 treatment arms.
  -  Arm I: Patients receive oral placebo daily in addition to standard care.
  -  Arm II: Patients receive oral selenium daily in addition to standard care.

Eligibility: DISEASE CHARACTERISTICS:
  Histopathologically confirmed non-muscle-invasive transitional cell carcinoma (TCC) of the bladder (< pT2 )
  PATIENT CHARACTERISTICS:
  -  Able to swallow pills
  -  Not pregnant
  -  Fertile patients must use effective contraception
  -  No other malignancy within the past 5 years
  -  No known hypersensitivity or adverse reactions to selenium
  -  No other serious medical or psychiatric illness that would preclude giving informed consent
  -  No condition that, in the opinion of the investigator, may interfere with the safety of the patient or the evaluation of the study objectives
  PRIOR CONCURRENT THERAPY:
  -  See Disease Characteristics
  -  More than 30 days since prior daily dietary supplements containing selenium
  -  No other concurrent selenium (contained in individual supplements, antioxidant mix, or multivitamin) intake
  -  No concurrent participation in another study involving a medical, surgical, nutritional, or lifestyle intervention
  -  Concurrent participation in the follow-up phase of another study allowed

Relevance to patient case: not relevant